Today, new formulations are in development for specific delivery of CGA in tumors; for example, by pectin nanoparticles on colon cancer [160], sialic acid-modified liposomes by recognizing Siglec-1 receptor on tumor-associated macrophages [161], chitosan nanoparticles for skin carcinogenesis treatment [162], or albumin-CGA nanoparticles [163]. This evidence concerns the gene ALB and neoplasm.